58142-99-7

Usage

Uses

Used in Pharmaceutical Industry:
Isoquinoline, 5-iodo(9CI) is used as a base component for the creation of medicinal drugs due to its unique structural properties. Its chemical reactivity allows for the synthesis of compounds with various therapeutic effects.
Isoquinoline, 5-iodo(9CI) is used as a precursor in the synthesis of compounds with anti-inflammatory properties, helping to alleviate inflammation and related symptoms in patients.
Isoquinoline, 5-iodo(9CI) is used as a precursor in the synthesis of compounds with antiallergenic properties, aiming to reduce allergic reactions and improve the quality of life for individuals with allergies.
Isoquinoline, 5-iodo(9CI) is used as a precursor in the synthesis of compounds with anticancer properties, contributing to the development of new treatments for various types of cancer.
It is important to handle Isoquinoline, 5-iodo(9CI) properly to ensure safety, as it is a chemical compound with potential hazards.

Upstream product

• 34784-04-8 5-bromoisoquinoline 
• 1125-60-6 isoquinolin-5-ylamine 
• 119-65-3 isoquinoline 
• 696-41-3 m-iodobenzaldehyde 
• 541-41-3 chloroformic acid ethyl ester 
• 22483-09-6 2,2-dimethoxyethylamine 

Downstream Products

• 856832-08-1 4-iodophthalimide 
• 6937-34-4 3-iodophthalic acid 
• 401916-13-0 5-iodo-8-nitroisoquinoline 
• 23687-27-6 8-aminoisoquinoline 
• 369652-57-3 2-(8-isoquinolineamino)-3-nitrobenzoic acid 
• 1474060-71-3 1-(5'-isoquinolinyl)-1-(3'',4'',5''-trimethoxyphenyl)ethylene 
• 939758-80-2 5-iodo-1,2,3,4-tetrahydroisoquinoline 

Relevant academic research and scientific papers

Cu(II)-Catalyzed Construction of Heterobiaryls using 1-Diazonaphthoquinones: A General Strategy for the Synthesis of QUINOX and Related P,N Ligands

An efficient and straightforward method was developed for the synthesis of heterobiaryls using easily available N-oxides and diazonaphthoquinones under cheap Cu(II) catalysis. The developed method offered QUINOX and related congeners in a simple manner. A wide scope of important heterobiaryls was achieved with high site selectivity. The synthesized naphthols were transformed into the privileged related P,N ligands. Suitable resolution methods can directly afford the corresponding axially chiral heterobiaryls.

PROCESS FOR PREPARING A COT INHIBITOR COMPOUND

Disclosed are syntheses of a Cot (cancer Osaka thyroid) inhibitor, which has the formula (I).

High-yield synthesis method of 5-iodoisoquinoline compound

The invention relates to a high-yield synthesis method of a 5-iodoisoquinoline compound. The method comprises the following steps: carrying out a stirring reaction on an isoquinoline compound, N-iodosuccinimide and an acid solution in a nitrogen atmosphere at a reaction temperature of 5 DEG C or below for 1-5 hours; after the reaction is finished, adding an alkali solution, and performing stirringto quench the reaction; and carrying out aftertreatment to obtain the 5-iodoisoquinoline compound, wherein the isoquinoline compound is isoquinoline, alkyl-substituted isoquinoline or halogen-substituted isoquinoline. According to the method, the 5-iodoisoquinoline compound can be prepared with high efficiency and high yield, the yield of the 5-position iodine substituted product is 80 wt% or more, the yield of the 5-iodoisoquinoline compound product is still 75wt% or more even in a pilot plant test process, and the method has high industrial application value and is suitable for industrial batch production.

Relative Reactivities of Three Isomeric Aromatic Biradicals with a 1,4-Biradical Topology Are Controlled by Polar Effects

Unexpectedly, the 5-dehydroquinoline radical cation was formed in the gas phase from the 5-iodo-8-nitroquinolinium cation upon ion-trap collision-activated dissociation. This reaction involves the cleavage of a nitro group to generate an intermediate monoradical, namely, the 8-dehydro-5-iodoquinolinium cation, followed by rearrangement through abstraction of a hydrogen atom from the protonated nitrogen atom by the radical site. Dissociation of the rearranged radical cation through elimination of an iodine atom generates the 5-dehydroquinoline radical cation. The mechanism was probed by studying isomeric biradicals and performing quantum chemical calculations. The 5-dehydroquinoline radical cation showed greater gas-phase reactivity toward dimethyl disulfide, cyclohexane, and allyl iodide than the isomeric 5,8-didehydroquinolinium cation, which is more reactive than the isomeric 5,8-didehydroisoquinolinium cation studied previously. All three isomers have a 1,4-biradical topology. The order of reactivity is rationalized by the vertical electron affinities of the radical sites of these biradicals instead of their widely differing singlet–triplet splittings.

ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG

The present invention relates to aryl linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhbiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG

The present invention relates to aryl linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhbiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

Structure-activity relationships for pyrido-, imidazo-, pyrazolo-, pyrazino-, and pyrrolophenazinecarboxamides as topoisomerase-targeted anticancer agents

Heterocyclic phenazinecarboxamides were prepared by condensation of aminoheterocycles and 2-halo-3-nitrobenzoic acids, followed by reductive ring closure and amidation. They showed similar inhibition of paired cell lines that underexpressed topo II or overexpressed P-glycoprotein, indicating a non topo II mechanism of cytotoxicity and indifference to P-glycoprotein mediated multidrug resistance. Compounds with a fused five-membered heterocyclic ring were generally less potent than the pyrido[4,3-a]phenazines. A 4-methoxypyrido[4,3-a]phenazine (IC50s 2.5-26 nM) gave modest (ca. 5 day) growth delays in H69/P xenografts with oral dosing.

Substituted phenyl farnesyltransferase inhibitors

Compounds of formula (I) or pharmaceutically acceptable salts thereof, inhibit farnesyltransferase. Methods for making the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

Studies of (Pd0-mediated) stille cross-coupling reactions of thiophenestannane with aryl halide derivatives

Stille (arylstannane) conditions used Pd0-mediated cross-coupling reactions for preparation of thiophene/aryl analogs. Different arylhalides were compared when coupled with heterometal (thiophenestannane) system. Comparable yields have now been obtained by Stille (arylstannane) couplings with different reactivity of arylhalides.